Analysis of α2-adrenergic receptors and effect of brimonidine on matrix metalloproteinases and their inhibitors in human ciliary body

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 9, 2009, Pages 4237-4243

  Ooi, Yen Hoong ^a   Oh, Dong Jin ^a   Rhee, Douglas J ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; BRIMONIDINE; ENZYME PRECURSOR; GELATINASE A; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MESSENGER RNA; PROMATRIX METALLOPROTEINASE 1; PROMATRIX METALLOPROTEINASE 2; PROMATRIX METALLOPROTEINASE 24; PROMATRIX METALLOPROTEINASE 3; PROMATRIX METALLOPROTEINASE 9; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; QUINOXALINE DERIVATIVE;

ADULT; AGED; ARTICLE; CELL LYSATE; CILIARY BODY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; ORGAN DONOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; UVEOSCLERAL OUTFLOW; VISUAL SYSTEM FUNCTION; WESTERN BLOTTING; ZYMOGRAPHY; CELL CULTURE; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; MIDDLE AGED; SMOOTH MUSCLE; TRANSCRIPTION INITIATION;

ADRENERGIC ALPHA-AGONISTS; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CELLS, CULTURED; CILIARY BODY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MATRIX METALLOPROTEINASES; MIDDLE AGED; MUSCLE, SMOOTH; QUINOXALINES; RECEPTORS, ADRENERGIC, ALPHA-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASES; TRANSCRIPTIONAL ACTIVATION;

EID: 70349251360     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2312     Document Type: Article

References (69)

1. Boland MV, Quigley HA. Risk factors and open-angle glaucoma: classification and application. J Glaucoma. 2007;14:166-172.
2. Brubaker RF. Clinical measurements of aqueous dynamics: implications for addressing glaucoma. In: Civan MM, ed. The Eye's Aqueous Humor. From Secretion to Glaucoma. Academic Press: San Diego; 1998;233-284.
3. Konstas AG, Stewart WC, Topouzis F, Tersis I, Holmes KT, Stangos NT. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am J Ophthalmol. 2001;131:729-733.
4. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514-1517.
5. Larsson L-I. Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination. Arch Ophthalmol. 2001;119:492-495.
6. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128:8-14.
7. Maus TL, Nau C, Brubaker RF. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents. Arch Ophthalmol. 1999;117:586-591.
8. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology. 1995;102:456-461.
9. 2-adrenoceptors. Trends Pharmacol Sci. 1991;12:62-67.
10. 2-adrenoceptor-subtype function. Trends Pharmacol Sci. 1997;18:445-458.
11. 2-adrenergic receptor. Science. 1987;238:650-656.
12. 2-adrenergic receptor subtype. Proc Natl Acad Sci USA. 1988; 85:6301-6305.
13. 2-adrenergic receptor subtype, the gene for which is located on chromosome 2. Proc Natl Acad Sci USA. 1990;87:5094-5098.
14. Mittag TW, Tormay A. Drug responses of adenylate cyclase in iris-ciliary body determined by adenine labeling. Invest Ophthalmol Vis Sci. 1985;26:39-40.
15. Gabelt BT, Robinson JC, Hubbard WC, et al. Apraclonidine and brimonidine effects on anterior ocular and cardiovascular physiology in normal and sympathectomized monkeys. Exp Eye Res. 1994;59:633-644.
16. Matsuo T, Cynader MS. Localization of alpha-2 adrenergic receptors in the human eye. Ophthalmic Res. 1992;24:231-219.
17. 2-adrenergic receptor subtypes in the anterior segment of the human eye with selective antibodies. Invest Ophthalmol Vis Sci. 1995;36:2729-2739.
18. Bylund DB, Chacko DM. Characterization of alpha2 adrenergic receptor subtypes in human ocular tissue homogenates. Invest Ophthalmol Vis Sci. 1999;40:2299-2306.
19. Bárány EH. Localized contraction and relaxation within the ciliary muscle of the vervet monkey (Cercopithecus ethiops). In: Rohen JW, ed. The Structure of the Eye: Second Symposium. Stuttgart, Germany: FK Schattauer Verlag;1965:287-311.
20. Bill A, Phillips I. Uveoscleral drainage of aqeous humor in human eyes. Exp Eye Res. 1971;21:275-281.
21. Bill A. Effects of atropine and pilocarpine on aqueous humour dynamics in cynomolgus monkeys (Macacairus). Exp Eye Res. 1967;6:120-125.
22. Townsend DJ, Brubaker RF. Immediate effect of epinephrine on aqueous formation in the normal human eye as measured by fluorophotometry. Invest Ophthalmol Vis Sci. 1980;19:256-266.
23. Schenker JI, Yablonski ME, Podos SM, Linder L. Fluorophotometric study of epinephrine and timolol in human subjects. Arch Ophthalmol. 1981;99:1212-1216.
24. 2α. Exp Eye Res. 1988;47:761-769.
25. Lütjen-Drecoll E, Tamm E. The effects of ocular hypotensive doses of PGF2 alpha-isopropylester on anterior segment morphology. Prog Clin Biol Res. 1989;312:437-446.
26. Weinreb RN, Kashiwagi K, Kashiwagi F, Tuskahara S, Lindsey JD. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997; 38:2772-2780.
27. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle: a study on cultured cells and tissue sections. Exp Eye Res. 1998;67:179-191.
28. El-Shabrawi Y, Eckhardt M, Berghold A, et al. Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasone. Eye. 2000;14:375-383.
29. Lindsey JD, Kashiwagi K, Boyle D, Kashiwagi F, Firestein GS, Weinreb RN. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res. 1996;15:869-875.
30. Anthony TL, Lindsey JD, Weinreb RN. Latanoprost's effects on TIMP-1 and TIMP-2 expression in human ciliary muscle cells. Invest Ophthalmol Vis Sci. 2002;43:3705-3711.
31. Oh DJ, Martin JL, Williams AJ, et al. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body following latanoprost. Invest Ophthalmol Vis Sci. 2006;47:953-963.
32. 2α on calcium efflux. Invest Ophthalmol Vis Sci. 1992;33:2679-2686.
33. Oh DJ, Martin JL, Williams AJ, Russell P, Birk DE, Rhee DJ. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2006;47:3887-3895.
34. Keramanos NK, Lamari F, Katsimpris J, Gartaganis S. Development of an HPLC method for determining the alpha2-adrenergic receptor agonist brimonidine in blood serum and aqueous humor of the eye. Biomed Chromatogr. 1999;13:86-89.
35. Tzovolou DN, Lamari F, Mela EK, Gartaganis SP, Karamanos. Capillary electrophoretic analysis of brimonidin in aqueous humor of the eye and blood sera and realtion of its levels with intraocular pressure. Biomed Chromatogr. 2000;14:301-305.
36. Acheampong AA, Small D, Baumgarten V, Welty D, Tang-Liu D. Formulation effects on ocular absorption of brimonidine in rabbit eyes. J Ocul Pharmacol Ther. 2002;18:325-337.
37. Sebe A, Keivonen SK, Fintha A, et al. Tranforming growth factorb- induced alpha-smooth muscle actin expression in renal proximal tubular cells is regulated by p38b mitogen-activated protein kinase, extracellular signal-regulated protein kinase 1,2 and the Smad signaling during epithelial-myofibroblast transdifferentiation. Nepthrol Dial Transplant. 2008;23:1537-1545.
38. Nagase H, Suzuki K, Morodomi T, Enghild JJ, Salvesen G. Activation mechanisms of the precursors of matrix metalloproteinases 1, 2 and 3. Matrix Suppl. 1992;1:237-244.
39. Wang N, Lindsey JD, Angert M. Latanoprost and matrix metalloproteinase- 1 in human choroid organ cultures. Curr Eye Res. 2001;22(3):198-207.
40. Hinz B, Rösch S, Ramer R. Latanoprost induces matrix metalloproteinase- 1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism. FASEB J. 2005;19(13):1929-1931.
41. Husain S, Jafri F, Crosson CE. Acute effects of PGF2alpha on MMP-2 secretion from human ciliary muscle cells: a PKC- and ERK-dependent process. Invest Ophthalmol Vis Sci. 2005;46(5):1706-1713.
42. Hatamochi A, Kuroda K, Shinkai H. Regulation of matrix metalloproteinase (MMP) expression in cutis laxa fibroblasts: upregulation of MMP-1, MMP-3 and MMP-9 genes but not of the MMP-2 gene. Br J Dermatol. 1998;138(5):757-762.
43. Kelley MJ, Rose AY, Song K, et al. Synergism of TNF and IL-1 in the induction of matrix metalloproteinase-3 in trabecular meshwork. Invest Ophthalmol Vis Sci. 2007;48(6):2634-2643.
44. Llano E, Pendás AM, Freije JP. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. Cancer Res. 1999;59(11): 2570-2576.
45. Qian LW, Xie J, Ye F. Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases. J Virol. 2007;81(13):7001-7010.
46. Sanka K, Maddala R, Epstein DL. Influence of actin cytoskeletal integrity on matrix metalloproteinase-2 activation in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2007; 48(5):2105-2114.
47. Conley SM, Bruhn RL, Morgan PV. Selenium's effects on MMP-2 and TIMP-1 secretion by human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2004;45(2):473-479.
48. Aihara M, Lindsey JD, Weinreb RN. Effect on diurnal intraocular pressure variation of eliminating the alpha-2 adrenergic receptor subtypes in the mouse. Invest Ophthalmol Vis Sci. 2008;49:929-933.
49. Khasigov PZ, Podobed OV, Gracheva TS, Salbiev KD, Grachev SV, Berezov TT. Role of matrix metalloproteinases and their inhibitors in tumor invasion and metastasis. Biochemistry (Mosc). 2003;68: 711-717.
50. Pauschinger M, Chandrasekharan K, Schultheiss JP. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system. Heart Fail Rev. 2004;9:21-31.
51. Steinmetz EF, Buckley C, Shames ML, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg. 2005;241:92-101.
52. Woessner JF. MMPs and TIMPs: an historical perspective. Methods Mol Biol. 2001;151:8-11.
53. Egawa N, Koshikawa N, Tomari T, Nabeshima K, Isobe T, Seiki M. Membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14) cleaves and releases a 22-kDa extracellular matrix metalloproteinase inducer (EMMPRIN) fragment from tumor cells. J Biol Chem. 2006;281(49):37576-37585.
54. Miyamori H, Takino T, Kobayashi Y, et al. Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane- type matrix metalloproteinases. J Biol Chem. 2001;276(30): 28204-28211.
55. Overall CM, Tam E, McQuibban GA, et al. Domain interactions in the gelatinase A. TIMP-2.MT1-MMP activation complex: the ectodomain of the 44-kDa form of membrane type-1 matrix metalloproteinase does not modulate gelatinase A activation. J Biol Chem. 2000;275(50):39497-39506.
56. Morrison CJ, Butler GS, Bigg HF, Roberts CR, Soloway PD, Overall CM. Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway. J Biol Chem. 2001; 276(50):47402-47410.
57. Morrison CJ, Overall CM. TIMP independence of matrix metalloproteinase (MMP)-2 activation by membrane type 2 (MT2)-MMP is determined by contributions of both the MT2-MMP catalytic and hemopexin C domains. J Biol Chem. 2006;281(36):26528-26539.
58. Knäuper V, Bailey L, Worley JR, Soloway P, Patterson ML, Murphy G. Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13. FEBS Lett. 2002;532(1-2):127-130.
59. Lafleur MA, Hollenberg MD, Atkinson SJ, Knäuper V, Murphy G, Edwards DR. Activation of pro-(matrix metalloproteinase-2) (pro- MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. Biochem J. 2001;357:107-115.
60. Knäuper V, Will H, López-Otin C, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation: evidence that MT1- MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem. 1996;271(29):17124-17131.
61. Hosseini M, Rose AY, Song K, et al. IL-1 and TNF induction of matrix metalloproteinase-3 by c-Jun N-terminal kinase in trabecular meshwork. Invest Ophthalmol Vis Sci. 2006;47(4):1469-1476.
62. Alexander JP, Acott TS. Involvement of the Erk-MAP kinase pathway in TNFalpha regulation of trabecular matrix metalloproteinases and TIMPs. Invest Ophthalmol Vis Sci. 2003;44(1):164-169.
63. Alexander JP, Acott TS. Involvement of protein kinase C in TNFalpha regulation of trabecular matrix metalloproteinases and TIMPs. Invest Ophthalmol Vis Sci. 2001;42(12):2831-2838.
64. Alexander JP, Samples JR, Van Buskirk EM, Acott TS. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci. 1991;32(1):172-180.
65. Wilhelm SM, Collier IE, Kronberger A, et al. Human skin fibroblast stromelysin: structure, glycosylation, substrate specificity, and differential expression in normal and tumorigenic cells. Proc Natl Acad Sci USA. 1987;84(19):6725-6729.
66. Chan CY, Chen YS, Ma MC, Chen CF. Remodeling of experimental arteriovenous fistula with increased matrix metalloproteinase expression in rats. J Vasc Surg. 2007;45:804-811.
67. English JL, Kassiri Z, Koskivirta I, et al. Individual TIMP deficiencies differentially impact pro-MMP-2 activation. J Biol Chem. 2006; 281:10337-10346.
68. Oshika T, Ariae M, Sugiyama T, Nakajima M, Azuma I. Effect of bunazosin hydrochloride on intraocular pressure and aqueous humor dynamics in normotensive human eyes. Arch Ophthalmol. 1991;109:1569-1574.
69. Akaishi T, Takagi Y, Matsugi T, Ishida N, Hara H, Kashiwagi K. Effects of bunazosin hydrochloride on ciliary muscle constriction and matrix metalloproteinase activities. J Glaucoma. 2004;13: 312-318.